Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Show more

660 Main Street, Woburn, MA, 01801, United States

https://www.biofrontera-us.com

Drug Manufacturers - Specialty & Generic

Healthcare

Start AI Chat

Market Cap

23.91M

52 Wk Range

$0.56 - $1.63

Previous Close

$1.61

Open

$1.64

Volume

639,418

Day Range

$1.54 - $1.66

Enterprise Value

25.34M

Cash

4.667M

Avg Qtr Burn

-1.658M

Insider Ownership

11.99%

Institutional Own.

20.72%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ameluz® - PDT (3 tubes) Details Actinic keratosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BF-RhodoLED® XL combo w/ Ameluz® Details Actinic keratosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XEPI (ozenoxacin) Details Impetigo	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ameluz (aminolevulinic acid hydrochloride) Details BCC (basal cell carcinoma), AK (actinic keratosis)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ameluz®-PDT combo w/ BF-RhodoLED® Details Superficial basal cell carcinoma	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ameluz® Details Actinic keratosis	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ameluz® Details Moderate to Severe Acne Vulgaris	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.